ContraVir Pharmaceuticals, Inc. (CTRV) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 17 transactions totaling $34.7K, demonstrating a bullish sentiment with $34.7K in net insider flow. The most recent transaction on Jan 3, 2018 involved a transaction of 100,654 shares valued at $0.
No significant insider buying has been recorded for CTRV in the recent period.
No significant insider selling has been recorded for CTRV in the recent period.
Based on recent SEC filings, insider sentiment for CTRV is bullish with an Insider Alignment Score of 100/100 and a net flow of $34.7K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at ContraVir Pharmaceuticals, Inc. (CTRV) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading CTRV stock, having executed 17 transactions in the past 90 days. The most active insider is James Sapirstein (Executive), who has made 6 transactions totaling $40.2K.
Get notified when executives and directors at CTRV file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 3, 2018 | T. Foster Robert | Executive | Award | 100,654 | $N/A | $0 | |
| Jan 3, 2018 | Sapirstein James | Executive | Award | 322,092 | $N/A | $0 | |
| Jan 3, 2018 | T. Cavan John | Executive | Award | 101,221 | $N/A | $0 | |
| Jul 6, 2017 | T. Foster Robert | Executive | Award | 44,082 | $N/A | $0 | |
| Jul 6, 2017 | Z. Sullivan-bolyai John | Executive | Award | 58,681 | $N/A | $0 | |
| Jul 6, 2017 | Sapirstein James | Executive | Award | 141,061 | $N/A | $0 | |
| Jul 6, 2017 | T. Cavan John | Executive | Award | 46,726 | $N/A | $0 | |
| Jun 20, 2017 | T. Cavan John | Executive | Purchase | 20,000 | $0.65 | $13.0K | |
| Oct 27, 2016 | Sapirstein James | Executive | Option Exercise | 16,666 | $1.50 | $25.0K | |
| Feb 18, 2016 | Sapirstein James | Executive | Purchase | 10,000 | $1.00 | $10.0K | |
| Nov 30, 2015 | Sapirstein James | Executive | Purchase | 500 | $2.15 | $1.1K | |
| Nov 23, 2015 | Sapirstein James | Executive | Purchase | 2,500 | $1.64 | $4.1K | |
| Mar 4, 2014 | P. Brancaccio John | Executive | Purchase | 4,393 | $1.49 | $6.5K | |
| Feb 18, 2014 | Inc. Synergy Pharmaceuticals, | Executive | Other | 9,000,000 | $N/A | $0 | |
| Feb 18, 2014 | P. Brancaccio John | Executive | Other | 2,015 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 5 | $34.7K | 58.1% |
Exercise(M) | 1 | $25.0K | 41.9% |
Award(A) | 7 | $0 | 0.0% |
Other(J) | 4 | $0 | 0.0% |
Insiders at ContraVir Pharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 8 insiders making 17 transactions totaling $34.7K in purchases versus $0 in sales, the net buying activity of $34.7K signals strong executive confidence. James Sapirstein (Executive) leads the buying activity with $40.2K in transactions across all time.